TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.010
+0.120 (3.08%)
Mar 25, 2026, 4:00 PM EDT - Market closed
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for TriSalus Life Sciences stock has a target of 7.00, which predicts a 74.56% increase from the current stock price of 4.01.
Price Target: $7.00 (+74.56%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for TriSalus Life Sciences is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +74.56% | Mar 9, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $7 | Strong Buy | Maintains | $12 → $7 | +74.56% | Mar 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +199.25% | Dec 17, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +174.31% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +174.31% | Jan 24, 2025 |
Financial Forecast
Revenue This Year
61.62M
from 45.15M
Increased by 36.47%
Revenue Next Year
85.84M
from 61.62M
Increased by 39.31%
EPS This Year
-0.25
from -1.84
EPS Next Year
0.21
from -0.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 64.1M | 95.9M | |||
| Avg | 61.6M | 85.8M | |||
| Low | 58.8M | 76.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 41.9% | 55.6% | |||
| Avg | 36.5% | 39.3% | |||
| Low | 30.2% | 23.7% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.11 | 0.22 |
| Avg | -0.25 | 0.21 |
| Low | -0.49 | 0.21 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.